Das Medizinportal     Aktuelles für medizinische Fachkreise

Das Medizinportal     Aktuelles für medizinische Fachkreise


Prophylaxe und Therapie sekundärer ZNS-Beteiligung bei malignen Lymphomen (S.10–15)
A. Korfel 

  1. Chin CK, Cheah CY. How I treat patients with aggressive lymphoma at high risk of CNS relapse. Blood. 2017; 130(7): 867–874
  2. Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, et al. and International Extranodal Lymphoma Study Group. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol. 2003; 21(1): 20–7
  3. Monnard V, Sun A, Epelbaum R, Poortmans P, Miller RC, et al. Primary spinal epidural lymphoma: patients' profile, outcome, and prognostic factors: a multicenter Rare Cancer Network study. Int J Radiat Oncol Biol Phys. 2006; 65(3): 817–23 
  4. Hosein PJ, Maragulia JC, Salzberg MP, Press OW, Habermann TM, et al. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. Br J Haematol. 2014; 165(3): 358–63 
  5. Papageorgiou SG, Diamantopoulos P, Levidou G, Angelopoulou MK, Economopoulou P, et al. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab. Hematol Oncol. 2013; 31(1): 10–7 
  6. Bekkenk MW, Postma TJ, Meijer CJ, Willemze R. Frequency of central nervous system involvement in primary cutaneous B-cell lymphoma. Cancer. 2000; 89(4): 913–9
  7. Murawski N, Held G, Ziepert M, Kempf B, Viardot A, et al. The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas. Blood. 2014; 124(5): 720–8 
  8. Korfel A. Prevention of central nervous system relapses in diffuse large B-cell lymphoma: which patients and how? Curr Opin Oncol. 2011; 23(5): 436–40
  9. Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, et al. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. J Clin Oncol. 2016 Sep 10; 34(26): 3150–6
  10. El-Galaly TC, Villa D, Michaelsen TY, Hutchings M, Mikhaeel NG, et al. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. Eur J Cancer. 2017; 75: 195–203
  11. Schmitz N, Zeynalova S, Glass B, Kaiser U, Cavallin-Stahl E, et al. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol. 2012; 23(5): 1267–73
  12. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009; 23; 113(17): 3896–902
  13. Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, et al. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer. 2012 Jun 1; 118(11): 2944–51
  14. Tai WM, Chung J, Tang PL, Koo YX, Hou X, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol. 2011; 90(7): 809–18
  15. Tomita N, Takasaki H, Ishiyama Y, Kishimoto K, Ishibashi D, et al. Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma. 2015; 56(3): 725–9
  16. Malecek MK, Petrich AM, Rozell S, Chu B, Trifilio S, et al. Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab. Am J Hematol 2017; 92(11): 1156–62 
  17. González-Barca E, Canales M, Salar A, Ferreiro-Martínez JJ, Ferrer-Bordes S, et al. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial. Ann Hematol 2016; 95(6): 893–9
  18. Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol 2011; 29(20): 2766–72 
  19. Haioun C, Besson C, Lepage E, Thieblemont C, Simon D, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 2000; 11(6): 685–90
  20. Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003; 102(13): 4284–9 
  21. Holte H, Leppä S, Björkholm M, Fluge O, Jyrkkiö S, et al. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol 2013; 24(5): 1385–92
  22. Cheah CY, Herbert KE, O'Rourke K, Kennedy GA, George A, et al. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. Br J Cancer 2014; 111(6): 1072–9 
  23. Ferreri AJ, Bruno-Ventre M, Donadoni G, Ponzoni M, Citterio G, et al. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. Brit J Haematol 2015; 168(5): 654–62 
  24. Glantz MJ, LaFollette S, Jaeckle KA, Shapiro W, Swinnen L, et al.Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999; 17(10): 3110–6
  25. Doolittle ND, Abrey LE, Shenkier TN, Tali S, Bromberg JE, et al. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood 2008; 111(3): 1085–93
  26. Patrij K, Reiser M, Wätzel L, Pels H, Kowoll A, et al. Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis. Ger Med Sci. 2011; 9: Doc11
  27.  Korfel A, Elter T, Thiel E, Hänel M, Möhle R, et al. Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica 2013; 98(3): 364–70
  28. Ferreri AJ, Donadoni G, Cabras MG, Patti C, Mian M, et al. High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial.J Clin Oncol 2015; 33(33): 3903–10
  29. Qualls D, Sullivan A, Li S, Brunner AM, Collier K, et al. High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement. Clin Lymphoma Myeloma Leuk, 17(12): 884–88
  30. Korfel A. “Wonder drugs” in CNS lymphoma. Translational Cancer Res 2017, Vol 6, Suppl 7 (October 2017) 

Radioonkologische Therapiemöglichkeiten bei zerebralen Metastasen (S.18–23)
R. Bodensohn, C. Belka,M. Niyazi 

  1. Soffietti R, Abacioglu U, Baumert B, Combs SE, Kinhult S, Kros JM, et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). NeuroOncol 2017 Feb 1; 19(2): 162−174
  2. Kocher M, Wittig A, Piroth MD, Treuer H, Seegenschmiedt H, Ruge M, et al. Stereotactic radiosurgery for treatment of brain metastases. A report of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlenther Onkol 2014; 190(6): 521–32
  3. Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, McColl E, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet 2016 Oct 22; 388(10055): 2004−14
  4. Wang TJC, Brown PD. Brainmetastases: fractionated whole-brain radiotherapy. Handb ClinNeurol. 2018; 149: 123−127 
  5. Bruynzeel AM, Lagerwaard FJ. Whole brain radiotherapy for brain metastases from non-small cell lung cancer: the end of an era? J ThoracDis. 2016 Nov; 8(11): E1525−27
  6. Gondi V, Tome WA, Mehta MP. Why avoid the hippocampus? A comprehensive review. Radiother Oncol. 2010; 97(3): 370–6
  7. Kazda T, Jancalek R, Pospisil P, Sevela O, Prochazka T, Vrzal M, et al. Why and how to spare the hippocampus during brain radiotherapy: the developing role of hippocampal avoidance in cranial radiotherapy. Radiat Oncol. 2014; 9: 139
  8. Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol. 2014; 32(34): 3810–6
  9. Oehlke O, Wucherpfennig D, Fels F, Frings L, Egger K, Weyerbrock A, et al. Whole brain irradiation with hippocampal sparing and dose escalation on multiple brain metastases : Local tumour control and survival. Strahlenther Onkol. 2015
  10. Harth S, Abo-Madyan Y, Zheng L, Siebenlist K, Herskind C et al. Estimation of intracranial failure risk following hippocampal-sparing whole brain radiotherapy. RadiotherOncol. 2013Oct; 109(1): 152−8
  11. Brown PD, Pugh S, Laack Nn, Wefel Js, Khuntia D, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013Oct; 15(10): 1429−37
  12. Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J RadiatOncol Biol Phys. 2000May 1; 47(2): 291−8
  13. Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol 2014 Apr; 15(4): 387−95
  14. Yamamoto M, Serizawa T, Higuchi Y, Sato Y, Kawagishi J, Yamanaka K, et al. A Multi-institutional Prospective Observational Study of Stereotactic Radiosurgery for Patients With Multiple Brain Metastases (JLGK0901 Study Update): Irradiation-related Complications and Long-term Maintenance of Mini-Mental State Examination Scores. Int J RadiatOncol Biol Phys. 2017 Sep 1; 99(1): 31−40
  15. Yamamoto M, Kawabe T, Sato Y, Higuchi Y, Nariai T, et al. Stereotactic radiosurgery for patients with multiple brain metastases: a case-matched study comparing treatment results for patients with 2-9 versus 10 or more tumors. JNeurosurg. 2014Dec; 121 Suppl: 16−25
  16. www.brainlab.com/wp-content/uploads/2015/09/RT_WP_EN_Automatic-Brain-Metastases-Planning_Sep15_final1.pdf. Zuletzt besucht am 27.12.2017
  17. Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J ClinOncol 2011 Jan 10; 29(2): 134−41
  18. Soffietti R, Kocher M, Abacioglu Um, Villa S, Fauchon F, et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol. 2013 Jan 1; 31(1): 65−72
  19. Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, Brown P, et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol 2017 Aug; 18(8): 1040−48
  20. Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017 Aug; 18(8): 1049−60
  21. Jiang T, Min W, Li Y, Yue Z, Wu C, Zhou C. Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis. Cancer Med. 2016 Jun; 5(6): 1055–65
  22. Sperduto PW, Wang M, Robins HI, Schell MC, Werner-Wasik M, et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys 2013 Apr 1; 85(5): 1312–8
  23. Wolf A, Zia S, Verma R, Pavlick A, Wilson M, Golfinos JG, et al. Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases. J Neurooncol 2016 May; 127(3): 607–15
  24. Xu Z, Lee CC, Ramesh A, Mueller AC, Schlesinger D, Cohen-Inbar O, et al. BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases. J Neurosurg. 2017 Mar; 126(3): 726–34
  25. Cochran DC, Chan MD, Aklilu M, Lovato JF, Alphonse NK, et al. The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery. J Neurosurg 2012 May; 116(5): 978–83 

Neoadjuvante Chemotherapie des Vulva-Karzinoms – Kasuistik und Literaturübersicht (S.30–33)
A. Hentrich, J. Kosse, G. Kläbisch, S. Braun, A. Rotmann, C. Jackisch 

  1.  Diagnosis, Therapy, and Follow - Up Care of Vulvar Cancer and its Precursors. National Guideline of the German Society of Gynecology and Obstetrics (S2k – Level, AWMF Registry No. 015/059, August 2015) www.awmf.org/leitlinien/detail/ll/015-059.html (Zugegriffen: 30.10.2016)
  2. Krebs in Deutschland 2011/2012. 10. Ausgabe. Robert Koch-Institut (Hrsg.) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg.). Berlin, 2015. www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2015/kid_2015_c51_vulva.pdf;jsessionid=120430184F486A489B7D828C80EC388C.2_cid363 (Zugegriffen: 30.10.2016)
  3. Raspagliesi F, Zanaboni F, Martinelli F, Scasso S, Laufer J, Ditto A. Role of paclitaxel and cisplatin as the neoadjuvant treatment for locally advanced squamous cell carcinoma of the vulva. J Gynecol 2014; 25: 22–29
  4. Deppe G, Mert I, Belotte J, Winer IS. Chemotherapy of vulvar cancer: a review. Wien Klin Wochenschr 2013; 125: 119–128
  5. Witteveen PO, Velden J, Vergote I Guerra C, Scarabeli C, Coens C, et.al. Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group); Ann Oncol 2009; 20: 1511–16
  6. Reade C, Eirikkson LR, Mackay H. Systemic therapy in squamous cell carcinoma of the vulva: current status and future directions. Gynecol Oncol 2014; 132: 780–789
  7. Horn LC, Schierle K. Pathologie der Präkanzerosen und der Karzinome von Vulva und Vagina sowie morphologische Prognosefaktoren. Onkologe 2009; 15: 15–27
  8. de Gregorio N, Schramm A, Ebner F, Janni W. Operative Therapie des Vulvakarzinoms – Wie viel Radikalität ist erforderlich? Geburtshilfe Frauenheilkd 2016; 76: 746–766
  9. Benedetti-Panici P, Greggi S, Scambia G, Salerno G, Mancuso S. Cisplatin (P), Bleomycin (B), and Methotrexate (M) preoperative chemotherapy in locally advanced vulvar carcinoma. Gynecol Oncol 1993; 50: 49–53
  10. Wagenaar HC, Colombo N, Vergote I, Hoctin-Boes G, Zanetta G, Pecorelli S, et.al. Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer. Gynecol Oncol 2001; 81: 348–354
  11. Geisler JP, Manahan KJ, Buller RE. Neoadjuvant chemotherapy in vulvar cancer: avoiding primary exenteration. Gynecol Oncol 2006; 100: 53–57
  12. Han SN, Vergote I, Amant F. Weekly paclitaxel/carboplatin in the treatment of locally advanced, recurrent, or metastatic vulvar cancer. Int J Gynecol Cancer 2012; 22: 865–868  

Infektionen bei Krebspatienten – Prävention und Therapie (S.34–39)
B. Hermann, M. von Lilienfeld-Toal, K. Mayer  

  1. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011; 52:e56-93. doi:10.1093/cid/cir073
  2. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966; 64:328–40
  3. Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47:8–32. doi:10.1016/j.ejca.2010.10.013
  4. Vehreschild JJ, Bohme A, Cornely OA, Kahl C, Karthaus M, Kreuzer K-A, et al. Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). Ann Oncol. 2014; 25:1709–18 doi:10.1093/annonc/mdu035
  5. Neumann S, Krause SW, Maschmeyer G, Schiel X, Lilienfeld-Toal M von. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2013; 92:433–42. doi:10.1007/s00277-013-1698-0
  6. Gafter-Gvili A, Fraser A, Paul M, Vidal L, Lawrie TA, van de Wetering, Marianne D, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012; 1:CD004386. doi:10.1002/14651858.CD004386.pub3
  7. Mayer K, Hahn-Ast C, Muckter S, Schmitz A, Krause S, Felder L, et al. Comparison of antibiotic prophylaxis with cotrimoxazole/colistin (COT/COL) versus ciprofloxacin (CIP) in patients with acute myeloid leukemia. Support Care Cancer 2015; 23:1321–9. doi:10.1007/s00520-015-2621-0
  8. Ford CD, Lopansri BK, Haydoura S, Snow G, Dascomb KK, Asch J, et al. Frequency, risk factors, and outcomes of vancomycin-resistant Enterococcus colonization and infection in patients with newly diagnosed acute leukemia: different patterns in patients with acute myelogenous and acute lymphoblastic leukemia. Infect Control Hosp Epidemiol 2015; 36:47–53. doi:10.1017/ice.2014.3
  9. Fridkin SK, Edwards JR, Courval JM, Hill H, Tenover FC, Lawton R, et al. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. Ann Intern Med. 2001; 135: 175–83
  10. Cometta A, Kern WV, Bock R de, Paesmans M, Vandenbergh M, Crokaert F, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 2003; 37:382–9. doi:10.1086/376637
  11. Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 2013; 98: 1826–35. doi:10.3324/haematol.2013.091025
  12. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730–51 doi:10.1086/339215
  13. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18:3038–51. doi:10.1200/jco.2000.18.16.3038
  14. Klastersky J, Paesmans M, Georgala A, Muanza F, Plehiers B, Dubreucq L, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 2006; 24:4129–34. doi:10.1200/JCO.2005.03.9909
  15. Kern WV, Cometta A, Bock R de, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1999; 341:312–8. doi:10.1056/NEJM199907293410502
  16. Rolston KVI, Frisbee-Hume SE, Patel S, Manzullo EF, Benjamin RS. Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients. Support Care Cancer. 2010; 18: 89–94. doi:10.1007/s00520-009-0634-2
  17. Bow EJ, Rotstein C, Noskin GA, Laverdiere M, Schwarer AP, Segal BH, et al. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis. 2006; 43:447–59. doi:10.1086/505393
  18. Cometta A, Calandra T, Gaya H, Zinner SH, Bock R de, Del Favero A, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Antimicrob Agents Chemother 1996; 40: 1108–15
  19. Maschmeyer G, Carratala J, Buchheidt D, Hamprecht A, Heussel CP, Kahl C, et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol 2015; 26: 21–33. doi:10.1093/annonc/mdu192
  20. Cometta A, Zinner S, Bock R de, Calandra T, Gaya H, Klastersky J, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 1995; 39: 445–52
  21. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999; 43: 1549–55
  22. Wingard JR. Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2004; 39 Suppl 1:S38-43. doi:10.1086/383052
  23. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56-93. doi:10.1093/cid/cir073
  24. Sandherr M, Hentrich M, Lilienfeld-Toal M von, Massenkeil G, Neumann S, Penack O, et al. Antiviral prophylaxis in patients with solid tumours and haematological malignancies – update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Hematol 2015; 94: 1441–50. doi:10.1007/s00277-015-2447-3
  25. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001; 98: 573–8
  26. Williams JV, Martino R, Rabella N, Otegui M, Parody R, Heck JM, Crowe JE, JR. A prospective study comparing human metapneumovirus with other respiratory viruses in adults with hematologic malignancies and respiratory tract infections. J Infect Dis 2005; 192: 1061–5. doi:10.1086/432732
  27. Hermann B, Lehners N, Brodhun M, Boden K, Hochhaus A, Kochanek M, et al. Influenza virus infections in patients with malignancies -- characteristics and outcome of the season 2014/15. A survey conducted by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO). Eur J Clin Microbiol Infect Dis 2016. doi:10.1007/s10096-016-2833-3
  28. Lilienfeld-Toal M von, Berger A, Christopeit M, Hentrich M, Heussel CP, Kalkreuth J, et al. Community acquired respiratory virus infections in cancer patients-Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology. Eur J Cancer 2016; 67:200–12. doi:10.1016/j.ejca.2016.08.015
  29. Boeckh M, Englund J, Li Y, Miller C, Cross A, Fernandez H, et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis 2007; 44: 245–9. doi:10.1086/509930
  30. Adams R, Christenson J, Petersen F, Beatty P. Pre-emptive use of aerosolized ribavirin in the treatment of asymptomatic pediatric marrow transplant patients testing positive for RSV. Bone Marrow Transplant 1999; 24: 661–4. doi:10.1038/sj.bmt.1701959
  31. McColl MD, Corser RB, Bremner J, Chopra R. Respiratory syncytial virus infection in adult BMT recipients: effective therapy with short duration nebulised ribavirin. Bone Marrow Transplant 1998; 21: 423–5. doi:10.1038/sj.bmt.1701091
  32. Englund JA, Piedra PA, Whimbey E. Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients. Am J Med 1997; 102: 61–70; discussion 75–6
  33. Ruhnke M, Bohme A, Buchheidt D, Cornely O, Donhuijsen K, Einsele H, et al. Diagnosis of invasive fungal infections in hematology and oncology – guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). Ann Oncol 2012; 23: 823–33. doi:10.1093/annonc/mdr407
  34. Tacke D, Buchheidt D, Karthaus M, Krause SW, Maschmeyer G, Neumann S, et al. Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Ann Hematol 2014; 93: 1449–56. doi:10.1007/s00277-014-2108-y
  35. Mousset S, Buchheidt D, Heinz W, Ruhnke M, Cornely OA, Egerer G, et al. Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2014; 93: 13–32. doi:10.1007/s00277-013-1867-1
  36. Maschmeyer G, Helweg-Larsen J, Pagano L, Robin C, Cordonnier C, Schellongowski P. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. J Antimicrob Chemother 2016; 71: 2405–13. doi:10.1093/jac/dkw158 

UPDATE: Therapie des metastasierten Prostatakarzinoms (S.41–45)
T. Steuber, G. v. Amsberg 

  1. Weiner AB et al. Increasing incidence of metastatic prostate cancer in the United States (2004-2013). Prostate Cancer Prostatic Dis. 2016 Dec; 19(4): 395–97
  2. Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002 May-Jun; 52(3): 154–79
  3. Tannock IF, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351(15): 1502–12
  4. Kellokumpu-Lehtinen PL et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol 2013; 14(2): 117–24
  5. Mita AC et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009; 15(2): 723–30
  6. de Bono JS et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376(9747): 1147–54
  7. De Bono JS et al. Phase III non-inferiority study of cabazitaxel (C) 20 mg/m2 (C20) versus 25 mg/m2 (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D). J Clin Oncol 34, 2016 (suppl; abstr 5008)
  8. Sartor AO et al. Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA). J Clin Oncol 34, 2016 (suppl; abstr 5006)
  9. Harris WP et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009; 6(2): 76–85
  10.  Logothetis CJ et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 2013; 13(12): 1210–7
  11. Scher HI et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367(13): 1187–97
  12. Armstrong AJ et al. Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2014; 32:5s, 2014: (suppl; abstr 5007)
  13. Parker C et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369(3): 213–23
  14. Lavaud P et al. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naive Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. Eur Urol 2017
  15. Maughan BL et al. Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study. Prostate 2017; 77(1): 33–40
  16. Terada N, et al. Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naive castration-resistant prostate cancer: The Kyoto-Baltimore collaboration. Int J Urol 2017; 24(6): 441–8
  17. Maines F et al. Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. Crit Rev Oncol Hematol 2015; 96(3): 498–506
  18. Caffo O et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015; 68(1): 147–53
  19. von Eyben FE et al. Third-line treatment and (177)Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging 2017
  20. Mateo J et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med 2015; 373(18): 1697–708
  21. Beer TM et al. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. J Clin Oncol 2017; 35(1): 40–7
  22. Kwon ED et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014; 15(7): 700–12
  23. Graff JN et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget 2016; 7(33): 52810–7
  24. Tucci M et al. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016 Apr; 69(4): 563–73
  25. Rydzewska LHM et al. STOPCaP Abiraterone Collaborators. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. Eur J Cancer 2017 Oct; 84: 88–101
  26. www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Prostata_5_0/LL_Prostata_Langversion_0_5_0.pdf
  27. Steuber T, Beyer B. Primary Tumor Treatment in Patients with Metastatic Prostate Cancer. Aktuelle Urol 2016 Sep; 47(5): 388–94
  28. Ost P et a. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol 2017 Dec 14: JCO2017754853